ASML: Strong Quarter, Uncertain Guidance
ASML beat top- and bottom-line expectations, growing sales by 24% and earnings per share by 47% in the quarter.
The company continues to see solid demand for its high-end lithography equipment used to make the powerful chips needed for AI data centers.
Tariffs and trade policy are clouding ASML's near-term outlook, leaving the company unable to say whether it will grow in 2026.
10 stocks we like better than ASML ›
Here's our initial take on ASML 's (NASDAQ: ASML) fiscal 2025 second-quarter financial report.
Key Metrics
Metric Q2 2024 Q2 2025 Change vs. Expectations
Net sales 6.2 billion euros 7.7 billion euros 24% Beat
EPS 4.01 euros 5.90 euros 47% Beat
New units sold 89 67 -25% n/a
Net bookings 5.6 billion euros 5.5 billion euros -2% n/a
ASML Management Is Unsure About 2026 Growth
ASML is the world's go-to supply of high-end lithography equipment used to manufacture microchips, with its most expensive systems selling for nearly $400 million each. The company stands to be a major beneficiary of the AI boom, which is fueling demand for more chips and the machines that produce them, but the high price of its systems tends to result in quarter-to-quarter choppiness.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
ASML posted revenue and earnings up 24% and 47% year over year despite selling fewer systems this quarter. Lithography equipment varies in price based on the sophistication of the device, implying that the company is seeing strong demand for its newer, cutting-edge technology. Net bookings in the quarter came in flat at 5.5 billion euros, of which 2.3 billion euros was for higher-end systems.
The company generated a gross margin of 53.7% in the quarter.
But the company is worried about storm clouds on the horizon. ASML's semiconductor customers have been dealing with heightened uncertainty due to trade restrictions and tariff policies, creating questions about orders heading into 2026.
CEO Christophe Fouquet said, "AI customers' fundamentals remain strong," but ASML is seeing "increasing uncertainty driven by macro-economic and geopolitical developments."
Fouquet said that while ASML is still preparing for growth in 2026, "we cannot confirm it at this stage."
Immediate Market Reaction
Investors were focused on the commentary about 2026, and not the second-quarter results. ASML shares were down 8% in premarket trading ahead of the New York Stock Exchange open.
What to Watch
Although ASML's cautious guidance about 2026 is weighing on investors post-earnings, the long-term growth story is still intact. The company is a vital piece in the supply of arguably one of the most important components of the global economy, and with AI spending and other digital efforts likely to continue to build for years to come, there should be solid demand for semiconductors and the machines needed to make them.
The geopolitical situation is rapidly changing. Just this week, the U.S. reversed a ban on Nvidia (NASDAQ: NVDA) selling its H20 chips in China. In a recorded interview posted on ASML's website accompanying earnings, the company's chief financial officer, Roger Dassen, attributed the second-quarter beat in part to tariffs having a "less negative" impact than anticipated.
If that trend continues, ASML's caution about 2026 could prove to be overly conservative.
Helpful Resources
Should you invest $1,000 in ASML right now?
Before you buy stock in ASML, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and ASML wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $679,653!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,308!*
Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 15, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
Keurig to Post Q2 Earnings: What Is in the Cards for Investors?
Keurig Dr Pepper Inc. KDP is scheduled to release second-quarter 2025 results on July 24, before the market opens. The company is expected to register top-line growth when it reports the quarterly results. The Zacks Consensus Estimate for quarterly revenues is pegged at $4.14 billion, indicating a 5.5% rise from the year-ago period's number. The consensus estimate for KDP's second-quarter earnings is pegged at 49 cents per share, suggesting 8.9% growth from 45 cents reported in the prior-year quarter. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) In the last reported quarter, the company delivered an earnings surprise of 10.53%. KDP has registered an earnings surprise of 3.1%, on average, in the trailing four quarters. What the Zacks Model Unveils for KDP Stock Our proven model does not conclusively predict an earnings beat for Keurig this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that's not the case here. You can uncover the best stocks before they're reported with our Earnings ESP Filter. Keurig has a Zacks Rank #3 at present and an Earnings ESP of -0.01%. Key Factors to Note Ahead of KDP's Q2 Results Keurig is well-positioned to deliver a strong second-quarter 2025 performance, building on the momentum of a solid first quarter. Continued brand strength, strategic pricing actions and innovation-led growth are expected to remain key drivers. The company's expansion initiatives and focus on product innovation are acting as tailwinds, while the Refreshment Beverages segment continues to show robust momentum. Additionally, the recent GHOST energy acquisition is likely to further boost results through enhanced market presence and incremental sales. In particular, the U.S. Refreshment Beverages segment is expected to remain a growth engine, led by sustained performance in the carbonated soft drinks (CSD) category. Brands like Dr Pepper, Canada Dry and 7UP are gaining share, supported by impactful innovations such as Dr Pepper Blackberry and 7UP Tropical. Emerging brands, including Electrolit and Bloom Sparkling Energy, are also gaining traction and are likely to have contributed meaningfully to second-quarter top-line growth. The GHOST acquisition has already delivered a solid start and is expected to accelerate results as integration continues. KDP's consumer-centric innovation strategy, backed by detailed scorecards measuring awareness, household penetration and loyalty, is expected to have supported continued market share gains in the quarter. The Zacks Consensus Estimate for Refreshment Beverages unit sales is pegged at $804 million, representing a year-over-year increase of 12.8%. On the international front, KDP anticipates improved growth in the second quarter, driven by late first-quarter price realization tied to inflation and the activation of stronger commercial strategies across key markets. In Mexico and Canada, momentum remains strong with brands like Penafiel, Crush and Dr Pepper, all of which benefit from strong local resonance. Continued pricing optimization and disciplined cost management are expected to have supported both top-line growth and margin expansion across international operations. However, the company continues to face inflationary pressures, particularly in its Coffee segment, which has remained sluggish for some time. The segment continues to grapple with elevated green coffee costs, reduced brewer shipments and cautious consumer spending. While KDP implemented early price increases to mitigate inflation, the uneven timing of industry-wide pricing created short-term volume and mix challenges. The Zacks Consensus Estimate for sales in the Coffee unit is $264 million, reflecting a year-over-year decline of 10.8%. Valuation Picture From a valuation perspective, Keurig stock is trading at a discount relative to historical and industry benchmarks. With a forward 12-month price-to-earnings ratio of 16.03x, which is well below the five-year high of 23.33x and the Beverages - Soft Drinks industry's average of 17.96x, the stock offers compelling value for investors seeking exposure to the sector. The recent market movements show that KDP's shares have risen 7.2% in the past six months compared with the industry's growth of 5.9%. Stocks With the Favorable Combination Here are some companies that, according to our model, have the right combination of elements to beat on earnings this reporting cycle. Anheuser-Busch InBev SA/NV BUD, aka AB InBev, currently has an Earnings ESP of +7.06% and a Zacks Rank of 3. The company is likely to register a decline in the top line when it reports second-quarter 2025 numbers. The consensus mark for revenues is pegged at $15.33 million, indicating a decline of 0.01% from the figure reported in the year-ago quarter. You can see the complete list of today's Zacks #1 Rank stocks here. The Zacks Consensus Estimate for AB InBev's quarterly earnings per share is 89 cents, implying a 1.1% decrease from the year-ago quarter. The consensus mark for earnings has fallen by 2 cents in the past 30 days. BUD has a trailing four-quarter earnings surprise of 10.9%, on average. Primo Brands Corporation PRMB currently has an Earnings ESP of +1.38% and a Zacks Rank of 3. PRMB is anticipated to register growth in its top and bottom lines when it reports second-quarter 2025 results. The Zacks Consensus Estimate for Primo Brands' quarterly revenues is pegged at $1.8 billion, indicating a surge of 275.5% from the figure reported in the prior-year quarter. The consensus estimate for Primo Brands' bottom line has moved down by 2 cents in the past 30 days to 43 cents per share. This implies growth of 65.4% from the year-ago quarter's figure. PRMB has delivered an earnings beat of 3.5%, on average, in the trailing four quarters. Altria Group, Inc. MO currently has an Earnings ESP of +1.03% and a Zacks Rank of 3. MO is anticipated to register top-line decline and bottom-line growth when it reports second-quarter 2025 results. The Zacks Consensus Estimate for Altria Group revenues is pegged at $5.2 billion, indicating a decline of 1.7% from the figure reported in the year-ago quarter. The consensus estimate for Altria's earnings has increased a penny in the past seven days to $1.37 per share. The consensus estimate implies a decline of 4.6% from the year-ago quarter's figure. MO has delivered an earnings beat of 1.3%, on average, in the trailing four quarters. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Altria Group, Inc. (MO): Free Stock Analysis Report Anheuser-Busch InBev SA/NV (BUD): Free Stock Analysis Report Keurig Dr Pepper, Inc (KDP): Free Stock Analysis Report Primo Brands Corporation (PRMB): Free Stock Analysis Report
Globe and Mail
8 minutes ago
- Globe and Mail
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
Danaher Corporation DHR is scheduled to release second-quarter 2025 results on July 22, before market open. The Zacks Consensus Estimate for revenues is pegged at $5.84 billion, which indicates an increase of 1.6% from the year-ago quarter's figure. The consensus mark for earnings is pinned at $1.64 per share, which has remained steady in the past 30 days. The estimate indicates a decrease of 4.7% from the figure reported in the year-ago quarter. The company's bottom line surpassed the Zacks Consensus Estimate in three of the preceding four quarters while missing the mark in one, the average beat being 8.5%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Let's see how things have shaped up for Danaher this earnings season. Key Factors and Estimates for Q2 Weakness in Danaher's protein consumables, flow cytometry and lab automation solutions businesses, due to lower demand across academic and government end-markets, is likely to have hurt the Life Sciences segment's revenues in the second quarter. Also, sales decline in the filtration business due to soft demand in the energy-related end market is likely to have impacted the segment's performance. We expect the segment's revenues to decrease 3.4% from the year-ago quarter to $1.71 billion. DHR has been witnessing escalating SG&A expenses, which are likely to weigh on its bottom-line results. For the quarter under review, we anticipate SG&A expenses to be $1.55 billion, indicating a 5.8% increase from the year-earlier level. The company has considerable exposure to overseas markets. Given its substantial international operations, foreign currency headwinds are likely to have marred its profitability. However, strength in the bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe and Southeast Asia, is expected to have aided the Biotechnology segment. The segment's performance is also likely to have benefited from solid momentum in the discovery and medical business. We expect the segment's revenues to increase 7% from the year-ago quarter to $1.83 billion. Solid momentum in the pathology and acute care diagnostics businesses is expected to drive the Diagnostics segment's results. We expect the segment's revenues to increase 1.1% from the year-ago quarter to $2.29 billion. Danaher acquired Abcam plc, a global supplier of protein consumables, in December 2023, which expanded the Life Sciences segment. Abcam's long track record of innovation, outstanding product quality and breadth of antibody portfolio are expected to have helped the company solve some pertinent healthcare challenges. Earnings Whispers Our proven model does not conclusively predict an earnings beat for DHR this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat, which is not the case here, as elaborated below. Earnings ESP: DHR has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at $1.64 per share. You can uncover the best stocks before they're reported with our Earnings ESP Filter. Zacks Rank: DHR presently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Stocks to Consider Here are some companies within the broader Medical sector, which according to our model, have the right combination of elements to beat on earnings in this reporting cycle. CVS Health Corporation CVS has an Earnings ESP of +2.06% and a Zacks Rank of 2 at present. The company is slated to release second-quarter 2025 results on July 31. CVS Health's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 18.1%. Cencora, Inc. COR has an Earnings ESP of +1.49% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2025 results on Aug. 6. Cencora's earnings surpassed the Zacks Consensus Estimate in each of the preceding four quarters, the average surprise being 6%. Amgen Inc. AMGN has an Earnings ESP of +0.07% and a Zacks Rank of 3 at present. The company is slated to release second-quarter 2025 results on Aug. 5. Amgen's earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 8.3%. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They include Stock #1: A Disruptive Force with Notable Growth and Resilience Stock #2: Bullish Signs Signaling to Buy the Dip Stock #3: One of the Most Compelling Investments in the Market Stock #4: Leader In a Red-Hot Industry Poised for Growth Stock #5: Modern Omni-Channel Platform Coiled to Spring Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%. Download Atomic Opportunity: Nuclear Energy's Comeback free today. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report
Globe and Mail
26 minutes ago
- Globe and Mail
Why Shares of Rigetti Computing Have Blasted 41% Higher This Week
Key Points The quantum computing company recently announced a big technological achievement. In a press release, Rigetti said its 36-qubit system had achieved a 99.5% median 2-qubit gate fidelity. 10 stocks we like better than Rigetti Computing › Since the close of trading last week, shares of the quantum computing company Rigetti Computing (NASDAQ: RGTI) had soared close to 41%, as of 9:31 a.m. ET Friday. The company earlier this week announced a new achievement on one of its quantum computing models. Twofold reduction in median error rate Rigetti announced in a press release that it had achieved a 99.5% median 2-qubit gate fidelity on its modular 36-qubit system, and a 2 times lower median 2-qubit gate error rate from the company's previous best on its 84-qubit model. Quantum computers are the next innovation of the traditional computer, and are supposed to be faster than even the best super computers today. While computers are built on the foundation of bits, tiny pieces of digital data that can take the form of a zero or one, quantum computers are built with qubits, which can take on more complex forms like a zero or one simultaneously. The 2-qubit gate fidelity essentially refers to accuracy. Quantum computers want to achieve higher fidelity and lower error rates. "We benefit from the many advantages of superconducting qubits, including gate speeds more than 1,000x faster than other modalities like ion trap and pure atoms, and scalability," Rigetti CEO Subodh Kulkarni said in a statement. "By leveraging well-known techniques from the semiconductor industry, we've developed proprietary technology that we believe is critical to enable scaling to higher qubit count systems." Technological progress is key Most quantum computing companies like Rigetti aren't generating significant earnings or revenue yet because they are still working to perfect the technology. They are really more like start-ups, so progress on the tech is everything and can excite investors. While Rigetti looks to have immense potential, the company already trades at a 5.5 billion market cap, so I'd caution investors from investing too heavily just yet. There's still a lot we don't know about quantum computing and the hurdles between the tech and actual commercialization. I'd keep positions smaller and more speculative for now. Should you invest $1,000 in Rigetti Computing right now? Before you buy stock in Rigetti Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rigetti Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $687,149!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,060,406!* Now, it's worth noting Stock Advisor's total average return is 1,072% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
